Skip to main content
SpringerLink
Log in
Book cover

Strahlentherapie pp 593–618Cite as

Ösophaguskarzinom und Karzinom des gastroösophagealen Überganges

  • Chapter
  • First Online:

  • 8882 Accesses

Zusammenfassung

Derzeit existiert keine nationale Leitlinie für die Diagnostik, Therapie und Nachsorge des Ösophaguskarzinoms. Das Erscheinen einer solchen Leitlinie ist für 2015 geplant (http://www.awmf.org/leitlinien/detail/anmeldung/1/ll/021-023OL.html).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

  • Abnet CC et al.(2009) Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 100(3): 551 557

    Google Scholar 

  • Ajani JA et al. (2011) Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 9(8): 830–887

    PubMed  Google Scholar 

  • Allum WH et al. (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 27(30): 5062–5067

    PubMed  Google Scholar 

  • Amenabar A., Hoppo T, Jobe BA (2013) Surgical management of gastroesophageal junction tumors. Semin Radiat Oncol, 23(1): 16–23

    PubMed  Google Scholar 

  • Ancon, E et al. (2008) Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 15(11): 3278–88

    Google Scholar 

  • Anderson LL, Lad TE (1982) Autopsy findings in squamous-cell carcinoma of the esophagus. Cancer 50(8): 1587–1590

    PubMed  CAS  Google Scholar 

  • Arnott SJ et al. (2005) Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev (4): CD001799.

    PubMed  Google Scholar 

  • Atkins BZ et al. (2004) Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg. 78(4): 1170–1176

    PubMed  Google Scholar 

  • Bang YJ et al. (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813): 315–321

    PubMed  CAS  Google Scholar 

  • Bang YJ et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376(9742):687–697

    PubMed  CAS  Google Scholar 

  • Barzi A, Lenz HJ (2012) Angiogenesis-related agents in esophageal cancer. Expert Opin Biol Ther. 12(10): 1335–1345

    PubMed  CAS  Google Scholar 

  • Baumhoer D, Ramadori G (2005) Ösophaguskarzinome - aktueller Stand der Diagnostik und Therapie. Z Gastroenterol 43(4): 399–409

    PubMed  CAS  Google Scholar 

  • Beatty JD, DeBoer G,. Rider WD (1979) Carcinoma of the esophagus: pretreatment assessment, correlation of radiation treatment parameters with survival, and identification and management of radiation treatment failure. Cancer. 43(6): 2254–2267

    PubMed  CAS  Google Scholar 

  • Bedard ELet al. (2001) The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer. 91(12): 2423–2430

    PubMed  CAS  Google Scholar 

  • Bedenne, L et al. (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 25(10): 1160–1168

    PubMed  CAS  Google Scholar 

  • Bennett C et al. (2012) Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 143(2): 336–346

    PubMed  Google Scholar 

  • Biere SS et al. (2012) Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 379(9829):1887–1892

    PubMed  Google Scholar 

  • Birkmeyer JD et al. (2002) Hospital volume and surgical mortality in the United States. N Engl J Med. 346(15): 1128–1137

    PubMed  Google Scholar 

  • Birkmeyer JD et al. (2003) Surgeon volume and operative mortality in the United States. N Engl J Med. 349(22): 2117–2127

    PubMed  CAS  Google Scholar 

  • Bleiberg H et al. (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 33(8): 1216–1220

    PubMed  CAS  Google Scholar 

  • Bollschweiler E, Holscher AH (2007) Prognosis of early esophageal cancer: differences between squamous cell carcinoma and adenocarcinoma. Ann Surg. 245(2): 334

    PubMed  Google Scholar 

  • Borchard, F (1985) Epidemiologie, Ätiologie und pathologische Anatomie des Ösophaguskarzinoms. in: Denck H, Paquet KJ, Zöckler CE (Hrsg.). Chirurgische Gastroenterologie mit interdisziplinären Gesprächen, TM Verlag, Hameln. Nr. 2(8/85): 7–15

    Google Scholar 

  • Bosset, JF et al. (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 337(3): 161–167

    PubMed  CAS  Google Scholar 

  • Brown, LM, Devesa SS, Chow WH (2008) Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 100(16): 1184–1187

    PubMed  Google Scholar 

  • Buas MF, Vaughan TL (2013) Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 23(1): 3–9

    PubMed  Google Scholar 

  • Buergy, D et al. (2012) Radiotherapy for tumors of the stomach and gastroesophageal junction–a review of its role in multimodal therapy. Radiat Oncol. 7: 192

    PubMed  Google Scholar 

  • Burmeister, BH et al. (2011) A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans Tasman Radiation Oncology Study TROG 03.07. J Thorac Oncol. 6(12): p. 2076–2082

    PubMed  Google Scholar 

  • zum Buschenfelde CM et al. (2011) (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 52(8): 1189–1196

    Google Scholar 

  • Bystricky B, Okines AF, Cunningham D (2011) Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 71(5): p. 541–555

    PubMed  CAS  Google Scholar 

  • Caspers RJ et al. (1993) Combined external beam and low dose rate intraluminal radiotherapy in oesophageal cancer. Radiother Oncol. 27(1): 7–12

    PubMed  CAS  Google Scholar 

  • Chakravarty T et al. (2010) Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 83(2): 581–586

    Google Scholar 

  • Conroy T et al. (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol. 14(1): 164–170

    PubMed  CAS  Google Scholar 

  • Cooper JS et al. (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 281(17): 1623–1627

    PubMed  CAS  Google Scholar 

  • Cooper SC et al. (2010) The risk of oesophageal cancer is not affected by a diagnosis of breast cancer. Eur J Cancer Prev, 2010. 19(3): p. 182–185

    PubMed  Google Scholar 

  • Corley A, Kubo A, Zhao W (2008) Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev. 17(2): 352–358

    PubMed  Google Scholar 

  • Cunningham D et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006. 355(1): 11–20

    PubMed  CAS  Google Scholar 

  • Cunningham E (2006) What is the registered dietitian’s role in the preoperative assessment of a client contemplating bariatric surgery? J Am Diet Assoc, 2006. 106(1): 163

    PubMed  Google Scholar 

  • Dantoc M, Cox MR, Eslick GD (2012) Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg. 147(8): 768–776

    PubMed  Google Scholar 

  • Das A et al. (2006) Association of esophageal adenocarcinoma with other subsequent primary cancers. J Clin Gastroenterol. 40(5): 405–411

    PubMed  Google Scholar 

  • Das D, Chilton AP, Jankowski JA, (2009) Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 181: 161–169

    PubMed  CAS  Google Scholar 

  • Dikken JL et al. (2013) Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg. 100(1): 83–94

    PubMed  CAS  Google Scholar 

  • Dikken JL et al. (2012) Influence of hospital type on outcomes after oesophageal and gastric cancer surgery. Br J Surg. 99(7): 954–963

    PubMed  CAS  Google Scholar 

  • Dikke JL et al. (2011) Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 11: 32.

    Google Scholar 

  • Djarv T, Lagergren P (2012) Quality of life after esophagectomy for cancer. Expert Rev Gastroenterol Hepatol. 6(1): 15–22

    Google Scholar 

  • Emami B et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 21(1):109–122

    PubMed  CAS  Google Scholar 

  • Engel LS et al. (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 95(18): 1404–1413

    PubMed  Google Scholar 

  • Erickson LA (2005) Sternberg’s Diagnostic Surgical Pathology, 4th ed. The American Journal of Surgical Pathology. 29(3): 425

    Google Scholar 

  • Fakhrian K et al. (2013) Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma. Strahlenther Onkol. 189(4): p. 293–300

    PubMed  CAS  Google Scholar 

  • Fiorica F et al. (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut, 53(7): p. 925–930

    PubMed  CAS  Google Scholar 

  • Flamen P et al. (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol, 2000. 18(18): 3202–1320

    PubMed  CAS  Google Scholar 

  • Freedman ND et al. (2007) A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 165(12):1424–1433

    PubMed  Google Scholar 

  • Freedman ND et al. (2011) Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 60(8): 1029–1037

    PubMed  Google Scholar 

  • Fritz P, Wannenmacher M (1997) Radiotherapy in the multimodal treatment of esophageal carcinoma. A review. Strahlenther Onkol. 173(6): 295–308

    PubMed  CAS  Google Scholar 

  • Fritz P et al. (2003) Concurrent chemotherapy and radiation therapy for unresectable locally advanced carcinoma of the esophagus. Phase II study and clinical review on literature. Strahlenther Onkol. 179(5): 328–36

    PubMed  Google Scholar 

  • Fujiwara Y et al. (2012) Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. Oncol Rep. 28(2): 446–452

    PubMed  CAS  Google Scholar 

  • Gebski V et al. (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol, 2007. 8(3): 226–234

    PubMed  CAS  Google Scholar 

  • de Geus-Oei, LF et al. (2012) FDG-PET/CT based response-adapted treatment. Cancer Imaging. 12(2): 324–335

    PubMed  Google Scholar 

  • Gignoux M et al. (1987) The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg. 11(4): 426–432

    PubMed  CAS  Google Scholar 

  • Greenwald BD et al. (2010) Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc. 71(4): 686–693

    PubMed  Google Scholar 

  • van Hagen P et al. (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366(22): 2074–2084

    PubMed  Google Scholar 

  • Haneder S et al. (2012) Assessment of renal function after conformal radiotherapy and intensity modulated radiotherapy by functional 1H-MR-imaging and 23Na-MR-imaging. Strahlenther Onkol Dec; 188 (12): 1146–1154

    Google Scholar 

  • Hardikar S et al. (2013) The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett’s esophagus. PLoS One. 8(1): p. e52192

    PubMed  CAS  Google Scholar 

  • Hasegawa S et al. (2013) Esophagus or stomach? The seventh TNM classification for Siewert type II/III junctional adenocarcinoma. Ann Surg Oncol. 20(3): 773–779

    PubMed  Google Scholar 

  • Herskovic A et al. (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med, 1992. 326(24): 1593–1598

    PubMed  CAS  Google Scholar 

  • Holscher, A.H et al. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg. 254(5): p. 802–7; discussion 807–8.

    Google Scholar 

  • Homs MY (2004) et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 364(9444): 1497–1504

    PubMed  Google Scholar 

  • Hsu FM et al. (2011) Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 81(4): e593–599

    PubMed  Google Scholar 

  • Huber K. (2013) Karzinom des Ösophagus und des gastroösophagealen Übergangs. Strahlentherapie und Onkologie February, Volume 189, ”/journal/66/189/2/page/Issue 2: 161–162

    Google Scholar 

  • Hulscher JB et al. (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 347(21): 1662–1669

    PubMed  Google Scholar 

  • Idelevich E et al. (2012) Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer. Onkologie. 35(7–8): 427–431

    PubMed  CAS  Google Scholar 

  • Ilson DH et al. (2007) Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 18(5): 898–902

    PubMed  CAS  Google Scholar 

  • Ilson,DH et al. (2012) Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 118(11): 2820–2822

    Google Scholar 

  • Isolauri J, Markkula H, (1989) Lye ingestion and carcinoma of the esophagus. Acta Chir Scand. 155(4–5): p. 269–71.

    PubMed  CAS  Google Scholar 

  • Jackson A et al. (2010) The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys. 76(3 Suppl): 155–160

    Google Scholar 

  • Jemal A et al. (2011) Global cancer statistics. CA Cancer J Clin. 61(2): 69–90

    PubMed  Google Scholar 

  • Kamangar F et al. (2006) Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 98(20): 1445–1452

    PubMed  Google Scholar 

  • Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24(14): 2137–2150

    PubMed  Google Scholar 

  • Kato K et al. (2011) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 81(3): 684–690

    PubMed  CAS  Google Scholar 

  • Kelsen DP et al. (2007) Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25(24): 3719–3725

    PubMed  Google Scholar 

  • Klautke G, Fietkau R, Significance of radiation therapy for adenocarcinomas of the esophagus, gastroesophageal junction and gastric cancer with special reference to the MAGIC trial. Strahlenther Onkol. 183(4): 163–169

    Google Scholar 

  • Kleinberg L (2013) Therapy for locally advanced adenocarcinoma of the gastroesophageal junction: optimizing outcome. Semin Radiat Oncol. 23(1): 38–50

    PubMed  Google Scholar 

  • Kmet J, Mahboubi E (1972) Esophageal cancer in the Caspian littoral of Iran: initial studies. Science. 175(4024): 846–853

    PubMed  CAS  Google Scholar 

  • Kole TP et al. (2012) Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 83(5): 1580–1586

    PubMed  Google Scholar 

  • Kranzfelder M et al. (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg. 98(6): 768–783

    PubMed  CAS  Google Scholar 

  • Krebs in Deutschland. 8. Ausgabe. http://www.rki.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2012/krebs_in_deutschland_2012.pdf?_blob=publicationFile. zugegriffen: 14. Juni 2013

  • Ku GY, Ilson DH (2012) Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. Gastrointest Cancer Res. 5(3): 85–92

    PubMed  Google Scholar 

  • Launois B et al. (1981) Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet. 153(5): 690–692

    PubMed  CAS  Google Scholar 

  • Lee, J et al. (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 30(3): 268–723

    PubMed  CAS  Google Scholar 

  • Liao LM et al. (2012) Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology, 2012. 142(3): p. 442–452 e5; quiz e22–3

    PubMed  CAS  Google Scholar 

  • Lightdale CJ (1995) Photodynamic therapy: a new light on Barrett’s esophagus. Gastrointest Endosc. 42(1): 96–98

    PubMed  CAS  Google Scholar 

  • Lin SH et al. (2012) Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys

    Google Scholar 

  • Lin SH et al. (2012) Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 83(3): e345–351

    PubMed  Google Scholar 

  • Lordick F et al. (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 8(9): 797–805

    PubMed  Google Scholar 

  • Lorenzen S et al. (2011) Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer. 11: 266

    PubMed  Google Scholar 

  • Lowe WC (1972) Survival with carcinoma of the esophagus. Ann Intern Med. 77(6): 915–918

    PubMed  CAS  Google Scholar 

  • Lutz MP et al. (2012) Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 48(16): 2941–2953

    PubMed  Google Scholar 

  • Macdonald JS et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345(10): 725–730

    PubMed  CAS  Google Scholar 

  • Malthaner R, Wong RK, Spithoff K (2010) Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol). 22(4): 250–256

    CAS  Google Scholar 

  • Marger RS, D. Marger D (1993) Carcinoma of the esophagus and tylosis. A lethal genetic combination. Cancer. 72(1): p.17–19

    PubMed  CAS  Google Scholar 

  • Mariette C, Piessen G (2012) Oesophageal cancer: how radical should surgery be? Eur J Surg Oncol. 38(3): 210–213

    PubMed  CAS  Google Scholar 

  • Matuschek C et al. (2011) Trimodal therapy in squamous cell carcinoma of the esophagus. Eur J Med Res. 16(10): 437–444

    PubMed  CAS  Google Scholar 

  • Matzinger O et al. (2009) EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol. 92(2): 164–175

    PubMed  Google Scholar 

  • Minsky BD et al. (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 20(5): 1167–1174

    PubMed  CAS  Google Scholar 

  • Nishihira T, Hirayama, K, Mori S, (1998) A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg. 175(1): 47–51

    PubMed  CAS  Google Scholar 

  • Nomura M et al. (2012) Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 82(2): 946–952

    PubMed  Google Scholar 

  • Nygaard K et al. (1992) Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 16(6): p. 1104–1109; discussion 1110

    PubMed  CAS  Google Scholar 

  • Offner FA (2000) Ätiologie, Molekularbiologie und Pathologie des Plattenepithelkarzinoms des Ösophagus. Der Pathologe. 21(5): 349–357

    PubMed  CAS  Google Scholar 

  • Oh DS, Demeester SR (2010) Pathophysiology and treatment of Barrett’s esophagus. World J Gastroenterol. 16(30): 3762–3772

    Google Scholar 

  • Ojala K et al. (1982) Symptoms of carcinoma of the oesophagus. Med J Aust. 1(9): 384–385

    PubMed  CAS  Google Scholar 

  • Orlando RC (2005) Pathogenesis of reflux esophagitis and Barrett’s esophagus. Med Clin North Am. 89(2): 219–241

    PubMed  Google Scholar 

  • Overholt BF et al. (2007) Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc. 66(3): p. 460–468

    PubMed  Google Scholar 

  • Pasini F et al. (2012) Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study. Cancer. 119(5): 939–945

    PubMed  Google Scholar 

  • Pennathur A et al. (2013) Oesophageal carcinoma. Lancet. 381(9864): 400–412

    PubMed  Google Scholar 

  • Perez CA., Brady LW, Halperin EC, (Hrsg) (2008) Perez and Brady’s principles and practice of radiation oncology : [now in color throughout and including fully searchable online text and image bank]. 5. ed. ed. Wolters Kluwer Health. Wolters Kluwer, Lippincott Williams & Wilkins: Philadelphia, Pa. [u.a.].

    Google Scholar 

  • Pohl H et al. (2013) Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 108(2): 200–207

    PubMed  Google Scholar 

  • Power DG, Ilson DH (2009) Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol. 1(3): 145–165

    PubMed  CAS  Google Scholar 

  • Qumseya BJ, David W, Wolfsen HC (2013) Photodynamic Therapy for Barrett’s Esophagus and Esophageal Carcinoma. Clin Endosc. 46(1): 0–7

    Google Scholar 

  • Rawat S et al. (2013) Chemoradiotherapy in the Management of Locally Advanced Squamous Cell Carcinoma Esophagus: Is Surgical Resection Required? J Gastrointest Cancer.

    Google Scholar 

  • Rice TW, Blackstone EH, and Rusch VW (2010) 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 17(7): p. 1721–1724

    PubMed  Google Scholar 

  • Rice TW et al. (2010) Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 116(16): 3763–3773

    PubMed  Google Scholar 

  • Richards et al. (2013) Results of docetaxel plus oxaliplatin (DOCOX) ±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study. European Journal of Cancer in press

    Google Scholar 

  • Robertson R, Coy P, Mokkhavesa S (1967) The results of radical surgery compared with radical radiotherapy in the treatment of squamous carcinoma of the thoracic esophagus. The case for preoperative radiotherapy. J Thorac Cardiovasc Surg. 53(3): 430–440

    PubMed  CAS  Google Scholar 

  • Ruhstaller T et al. (2011) Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol. 29(6): 626–631

    PubMed  CAS  Google Scholar 

  • Sack H, Thesen N (1998) Bestrahlungsplanung, 2. Aufl., Thieme, Stuttgart New York.

    Google Scholar 

  • Sadeghi S et al. (2008) Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev. 17(5): 1169–1178

    Google Scholar 

  • Sahgal A et al. (2012) Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 82(1): 107–116

    PubMed  Google Scholar 

  • Sakuramoto S et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357(18): 1810–1820

    PubMed  CAS  Google Scholar 

  • Sandler RS et al. (1995) The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA. 274(17): 1359–1362

    PubMed  CAS  Google Scholar 

  • Schieman C et al. (2013) Salvage resections for recurrent or persistent cancer of the proximal esophagus after chemoradiotherapy. Ann Thorac Surg. 95(2): p. 459–463

    PubMed  Google Scholar 

  • Shaheen NJ, Spechler SJ (2008) Total endoscopic eradication of Barrett’s esophagus: study methodology, candidate selection, and clinical outcomes. Endoscopy. 40(12): 994–999

    PubMed  CAS  Google Scholar 

  • Sharma P (2009) Clinical practice. Barrett’s esophagus. N Engl J Med. 361(26): 2548–2556

    PubMed  CAS  Google Scholar 

  • Shridhar R et al. (2013) Radiation therapy and esophageal cancer. Cancer Control. 20(2): 97–110

    PubMed  Google Scholar 

  • Siewert JR et al. (2001) Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 234(3): 360–367; discussion 368–369

    PubMed  CAS  Google Scholar 

  • Siewert JR et al. (1987) Kardiakarzinom: Versuch einer therapeutisch relevanten Klassifikation. Chirurg. 58(1): 25–32

    PubMed  CAS  Google Scholar 

  • Siewert JR, Stein HJ, Feith M (2006) Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 95(4): 260–269

    Google Scholar 

  • Sjoquist KM et al. (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12(7): 681–692

    Google Scholar 

  • Smit JK et al. (2013) Survival after Definitive (Chemo)Radiotherapy in Esophageal Cancer Patients: A Population-Based Study in the North-East Netherlands. Ann Surg Oncol.Jun; 20(6): 1985–1992

    Google Scholar 

  • Stahl M et al. (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 23(10): 2310–2317

    Google Scholar 

  • Stahl M et al. (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 27(6): 851–856

    Google Scholar 

  • Sterzing F, Grenacher L, Debus J (2012) Radiotherapy of gastroesophageal junction cancer. Recent Results Cancer Res. 196: 187–99

    Google Scholar 

  • Stieler F et al. (2011) A comparison of several modulated radiotherapy techniques for head and neck cancer and dosimetric validation of VMAT. Radiother Oncol. 101(3): 388–393

    Google Scholar 

  • Suh YS et al. (2012) Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 255(5): 908–915

    Google Scholar 

  • Suzuki A et al. (2011) Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 117(21): 4823–4833

    Google Scholar 

  • Saarländisches Krebsregister 2012.

    Google Scholar 

  • Teniere P et al. (1991) Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet. 173(2): 123–130

    Google Scholar 

  • Thrift AP et al. (2013) A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 11(2): p. 138–44 e2

    Google Scholar 

  • Urba SG et al. (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 19(2): 305–313

    Google Scholar 

  • Urschel JD, Vasan (2003), A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 185(6): 538–543

    Google Scholar 

  • Vakil N et al. (2001) A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol. 96(6): p. 1791–1796

    Google Scholar 

  • Vaughan.L et al. (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 6(12): 945–952

    Google Scholar 

  • Vaughan TL, Kiemeney LA, McKnight B (1995) Colorectal cancer in patients with esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 4(2): 93–97

    Google Scholar 

  • Walsh TN et al. (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 335(7): 462–467

    Google Scholar 

  • Wang, DB et al. (2012) Neoadjuvant Chemoradiotherapy Could Improve Survival Outcomes for Esophageal Carcinoma: A Meta-Analysis. Dig Dis Sci.

    Google Scholar 

  • Wara WM et al. (1976) Palliation for carcinoma of the esophagus. Radiology. 121(3 Pt. 1): 717–720

    Google Scholar 

  • Weber WA et al. (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 19(12): 3058–3065

    Google Scholar 

  • Welsh J et al. (2011) Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 81(5): 1336–1342

    Google Scholar 

  • van Westreenen HL et al. (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 22(18): 3805–3812

    Google Scholar 

  • Whiteman DC et al. (2010) Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology. 139(1): 73–83; quiz e11–2

    Google Scholar 

  • Wittekind C (Hrsg) (2010) TNM-Klassifikation maligner Tumoren. 7. Aufl. Wiley-Blackwell: Weinheim. XIX, 295

    Google Scholar 

  • Wong RK et al. (2003) Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys. 55(4): 930–942

    Google Scholar 

  • Wu AJ, Goodman KA (2013) Positron emission tomography imaging for gastroesophageal junction tumors. Semin Radiat Oncol. 23(1): 10–15

    Google Scholar 

  • Yamamoto M et al. (1997) Reevaluation of postoperative radiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 37(1): 75–78

    Google Scholar 

  • Huber K (2013) Überleben durch neoadjuvante Radiochemotherapie verbessert Strahlenther Onkol. 189(2): 161–162

    Google Scholar 

  • Ychou M et al. (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 29(13): 1715–1721

    Google Scholar 

  • Yoo C et al. (2012) Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. Ann Thorac Surg. 94(6): 1862–1868

    Google Scholar 

  • Yoon HH et al. (2012) Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 30(32): 3932–3938

    Google Scholar 

  • Yu C et al. (2012) Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J Cancer Res Clin Oncol. 138(2): 255–259

    Google Scholar 

  • Zhu WG et al. (2012) A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol.

    Google Scholar 

  • Zieren HU et al. (1995) Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg. 19(3): 444–449

    Google Scholar 

  • Zimmermann JS, Kumpf L, Kimmig B (1998) Variability of individual normal tissue radiation sensitivity. An international empirical evaluation of endogenous and exogenous response modifiers. Strahlenther Onkol. 174 Suppl 3: 16–19

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin Mannheim, Universität Heidelberg, Teodor-Kutzer-Ufer 1–3, D-68259, Mannheim, Deutschland

    J. Boda-Heggemann

  2. Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland

    D. Bürgy

  3. chirurgische Klinik, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, Haus 9,, 68167, Mannheim, Deutschland

    U. Ronellenfitsch

  4. Klinik für Radio-Onkologie, St. Marienkrankenhaus, Kampenstr. 51, D-57072, Siegen, Deutschland

    P. Fritz

  5. Klinik für Strahlentherapie und Radioonkologie, Universitätsmedizin MannheimTheodor-Kutzer Ufer 1-3, D-68167,, Mannheim, Deutschland

    F. Lohr

Authors
  1. J. Boda-Heggemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Bürgy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Ronellenfitsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Fritz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Lohr
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinikum Heidelberg, Heidelberg, Germany

    Michael Wannenmacher

  2. Universitätsklinikum Mannheim, Mannheim, Germany

    Frederik Wenz

  3. Universitätsklinikum Heidelberg, Heidelberg, Germany

    Jürgen Debus

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Boda-Heggemann, J., Bürgy, D., Ronellenfitsch, U., Fritz, P., Lohr, F. (2013). Ösophaguskarzinom und Karzinom des gastroösophagealen Überganges. In: Wannenmacher, M., Wenz, F., Debus, J. (eds) Strahlentherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-88305-0_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-88305-0_20

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-88304-3

  • Online ISBN: 978-3-540-88305-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation